10 documents found, page 1 of 1
Hospitalization of symptomatic patients with heart failure and moderate to seve...
Ponikowski, Piotr; Friede, Tim; von Bardeleben, Ralph Stephan; Butler, Javed; Shahzeb Khan, Muhammad; Diek, Monika; Heinrich, Jutta; Geyer, MartinBackground: For patients with functional mitral regurgitation (FMR) and symptomatic heart failure (HF), randomized trials of mitral transcatheter edge-to-edge repair (M-TEER) have produced conflicting results. Objectives: This study sought to assess the impact of M-TEER on hospitalization rates, and explore the effects of M-TEER on patients who did or did not have a history of recent HF hospitalizations before ...
Patiromer facilitates angiotensin inhibitor and mineralocorticoid antagonist th...
Pitt, Bertram; Anker, Stefan D.; Lund, Lars H.; Coats, Andrew J. S.; Filippatos, Gerasimos; Rossignol, Patrick; Weir, Matthew R.; Friede, TimBackground: Hyperkalemia (HK) is associated with suboptimal renin-angiotensin system (RAS) inhibitor and mineralocorticoid receptor antagonist (MRA) use in heart failure with reduced ejection fraction (HFrEF). Objectives: This study sought to assess characteristics and RAS inhibitor/MRA use in patients receiving patiromer during the DIAMOND (Patiromer for the Management of Hyperkalemia in Subjects Receiving RAA...
Percutaneous repair of moderate‐to‐severe or severe functional mitral regurgita...
Anker, Stefan D.; Friede, Tim; von Bardeleben, Ralph Stephan; Butler, Javed; Khan, Muhammad Shahzeb; Diek, Monika; Heinrich, Jutta; Geyer, MartinAim: The RESHAPE-HF2 trial is designed to assess the efficacy and safety of the MitraClip device system for the treatment of clinically important functional mitral regurgitation (FMR) in patients with heart failure (HF). This report describes the baseline characteristics of patients enrolled in the RESHAPE-HF2 trial compared to those enrolled in the COAPT and MITRA-FR trials. Methods and results: The RESHAPE-HF...
Repurposing the β3-adrenergic receptor agonist Mirabegron in patients with stru...
Balligand, Jean-Luc; Brito, Dulce; Brosteanu, Oana; Casadei, Barbara; Depoix, Christophe; Edelmann, Frank; Ferreira, Vanessa; Filippatos, GerasimosImportance: Left ventricular (LV) hypertrophy contributes to the onset and progression of heart failure (HF), particularly for patients with pre-HF (stage B) for whom no treatment has yet proven effective to prevent transition to overt HF (stage C). The β3-adrenergic receptors (β3ARs) may represent a new target, as their activation attenuates LV remodeling. Objective: To determine whether activation of β3ARs by...
Sex-stratified patterns of emergency cardiovascular admissions prior and during...
Gajewski, Piotr; Błaziak, Mikołaj; Urban, Szymon; Garus, Mateusz; Braunschweig, Frieder; Caldeira, Daniel; Gawor, Antoni; Greenwood, John P.The COVID-19 pandemic has had a significant impact on global public health, with long-term consequences that are still largely unknown. This study aimed to assess the data regarding acute cardiovascular hospital admissions in five European centers before and during the pandemic. A multicenter, multinational observational registry was created, comparing admissions to the emergency departments during a 3-months p...
Patiromer for the management of hyperkalemia in heart failure with reduced ejec...
Butler, Javed; Anker, Stefan D.; Lund, Lars H; Coats, Andrew J. S.; Filippatos, Gerasimos; Siddiqi, Tariq Jamal; Friede, Tim; Fabien, VincentAims: To investigate the impact of patiromer on the serum potassium level and its ability to enable specified target doses of renin-angiotensin-aldosterone system inhibitor (RAASi) use in patients with heart failure and reduced ejection fraction (HFrEF). Methods and results: A total of 1642 patients with HFrEF and current or a history of RAASi-related hyperkalemia were screened and 1195 were enrolled in the run...
Patient profiling in heart failure for tailoring medical therapy: a consensus d...
Rosano, Giuseppe M. C.; Moura, Brenda; Metra, Marco; Böhm, Michael; Bauersachs, Johann; Ben Gal, Tuvia; Adamopoulos, Stamatis; Abdelhamid, MagdyDespite guideline recommendations and available evidence, implementation of treatment in heart failure (HF) is poor. The majority of patients are not prescribed drugs at target doses that have been proven to positively impact morbidity and mortality. Among others, tolerability issues related to low blood pressure, heart rate, impaired renal function or hyperkalaemia are responsible. Chronic kidney disease plays...
Trimetazidine in cardiovascular medicine
Marzilli, Mario; Vinereanu, Dragos; Lopaschuk, Gary; Chen, Yundai; Dalal, Jamshed J; Danchin, Nicolas; Etriby, El; Ferrari, RobertoAbnormalities of myocardial energy metabolism appear as a common background of the two major cardiac disorders: ischemic heart disease (IHD) and heart failure (HF). Myocardial ischemia has been recently conceived as a multifaceted syndrome that can be precipitated by a number of mechanisms including metabolic abnormalities. HF is a progressive disorder characterised by a complex interaction of haemodynamic, neu...
Acute heart failure : lessons learned, roads ahead
Ferrari, Roberto; Bueno, Héctor; Chioncel, Ovidiu; Cleland, John G.; Stough, Wendy Gattis; Lettino, Maddalena; Metra, Marco; Parissis, John T.Acute heart failure remains a major challenge for clinicians and healthcare systems. The number of annual hospitalizations for acute heart failure is rising due to the aging of the general population and the increasing prevalence of heart failure. Heart failure is the leading cause of unplanned hospitalizations for patients older than 65 years in developed countries.1–4 These acute events impact the natural his...
Rationale and design of a multicentre, randomized,placebo-controlled trial of m...
Pouleur, Anne-Catherine; Anker, Stefan; Brito, Dulce; Brosteanu, Oana; Hasenclever, Dirk; Casadei, Barbara; Edelmann, Frank; Filippatos, GerasimosAims: Progressive left ventricular (LV) remodelling with cardiac myocyte hypertrophy, myocardial fibrosis, and endothelial dysfunction plays a key role in the onset and progression of heart failure with preserved ejection fraction. The Beta3‐LVH trial will test the hypothesis that the β3 adrenergic receptor agonist mirabegron will improve LV hypertrophy and diastolic function in patients with hypertensive struc...